CSANZ 2019

Mathew Maurer

Mathew Maurer

Professor of Cardiology, Columbia University, USA

Dr Maurer is a general internist and geriatric cardiologist with advanced training in heart failure and cardiac transplantation. He is the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University, College of Physicians and Surgeons, where directs the Clinical Cardiovascular Research Laboratory for the Elderly (CCRLE) at the Allen Hospital of NewYork Presbyterian Hospital. Dr Maurer is a member of the Advanced Cardiac Care Center at NewYork Presbyterian Hospital – Columbia Campus.

Dr Maurer received a B.S. in biomedical science as part of the seven-year medical school program at CCNY – The Sophie Davis School of Biomedical Education, where he was awarded the Belle Zeller Scholarship. He received his M.D. degree from Mount Sinai School of Medicine and graduated Alpha Omega Alpha. He completed training in internal medicine and cardiology at NewYork Presbyterian Hospital and was Chief Medical Resident.

Dr Maurer’s work focuses on evaluating age-related changes in cardiovascular physiology in order to elucidate the mechanism that underlies the higher prevalence and incidence of cardiovascular disease in older individuals. In much of his research he has focused on the following cardiovascular syndromes – (1) Syncope (fainting), falls and their relationship to disordered blood pressure regulation and (2) Heart failure in the setting of a normal ejection fraction including, (3) Hypertrophic Cardiomyopathy and (4) Cardiac amyloidosis. He has received funding from the National Institute on Aging and National Heart, Lung and Blood Institute to support his research activities.

He has published over 180 articles including peer-reviewed manuscripts, reviews and book chapters. He was chair of the American College of Cardiology’s Geriatric Cardiology Member Section, which is the largest organization dedicated to advancing the care of older adults with cardiovascular disease. He was co-chair of the Steering Committee of the ATTR-ACT trial showing tafamidis was a safe and effective therapy for transthyretin amyloid cardiomyopathy. Throughout his career, he has promulgated an approach to older adults with cardiovascular disease that offers the best of both geriatric and cardiovascular medicine in which a comprehensive holistic approach to enhance functional capacity and quality of life is at the forefront of emerging techniques to address cardiovascular physiologic derangement that disproportionately afflicts older adults.

Back to speakers